FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: A GISCAD multicenter phase II study

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 6, 2012, Pages 1641-1645

  Zaniboni, Alberto ^a   Aitini, Enrico ^b   Barni, Sandro ^c   Ferrari, Daris ^d   Cascinu, Stefano ^e   Catalano, Vincenzo ^f   Valmadre, Giuseppe ^g   Ferrara, Domenica ^h   Veltri, Enzo ⁱ   Codignola, Claudio ^j   Labianca, Roberto ^k  

^a Fondazione Poliambulanza   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

^c Treviglio Caravaggio Hospital   (Italy)

^d SAN PAOLO HOSPITAL   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f Ospedali Riuniti Marche Nord   (Italy)

^g Ospedale di Sondalo   (Italy)

^h SAN CARLO HOSPITAL   (Italy)

ⁱ Medical Oncology Unit   (Italy)

^j Fondazione Poliambulanza   (Italy)

^k OSPEDALI RIUNITI   (Italy)

more..

Author keywords

Chemotherapy; FOLFIRI; Irinotecan; Pancreatic cancer; Second line

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER CONTROL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LIVER DISEASE; LIVER DYSFUNCTION; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 84863809711     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1875-1     Document Type: Article

References (23)

1. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS (2007) National failure to operate on early stage pancreatic cancer. Ann Surg 246:173-180
2. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM), Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28:1645-1651
3. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A, GERCOR, GISCAD (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966
5. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513-5518
6. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825
7. Ko AH (2011) FOLFIRINOX: a small step or a great leap forward? J Clin Oncol 29:3727-3729
8. Boeck S, Heinemann V (2008) The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol 4:41-50
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,MooneyM, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
10. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
11. Kaplan EL, Meier P (1961) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
12. Custodio A, Puente J, Sastre J, Díaz-Rubio E (2009) Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions. Cancer Treat Rev 35:676-684
13. Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK (2009) Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 63:1141-1145
14. Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G (2010) Irinotecan plus bolus/infusional 5-fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 33:461-464
15. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL (2009) A randomised phase II study of modified FOLFIRI.3 versus modified FOLFOX as second-line therapy in patients with gemcitabine- refractory advanced pancreatic cancer. Br J Cancer 101: 1658-1663
16. Taïeb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru P, Fallik D, Spano JP, Landi B, Lledo G, Desrame J (2007) FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 18:498-503
17. Cereda S, Reni M, Rognone A, Ghidini M, Belli C, Longoni S, Fugazza C, Brioschi M, Nicoletti R, Balzano G, Passoni P, Villa E (2010) XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer. Anticancer Res 30:4785-4790
18. Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine Lefèvre L, Raymond E, Ruszniewski P, Louvet C, Hammel P (2011) FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: a retrospective series of 70 patients. J Clin Oncol 29 (suppl 4 abstract):272
19. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47:1676-1681
20. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA (2008) Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113:2046-2052
21. Hosein PJ, de Lima Lopes G Jr, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM (2012) A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol Feb 2. (Epub ahead of print)
22. Dimou AT, Syrigos KN, Saif MW (2011) Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights fromthe ''2011ASCOGastrointestinalCancers Symposium''. San Francisco, CA, USA. January 20-22, 2011. JOP 12:114-116
23. National Cancer Institute, National Institutes of Health, US Department of Health and Human Services (2010) COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE), ver 4.03, June 2010. (URL: http://evs.nci.nih.gov/ftp1/ CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf)